OncoMed Pharmaceuticals Inc., of Redwood City, Calif., began a Phase Ib/II trial of its anti-Notch2/3 antibody (OMP-59R5), triggering an $8 million milestone payment from GlaxoSmithKline plc, of London

and GlaxoSmithKline plc will pay generous dividends over the next decade

A combination LAMA/LABA inhaler is a logical development since standard treatment of COPD begins with a product like Spiriva, and then advances to combination treatment, such as Spiriva plus Symbicort (formoterol and budesonide, AstraZeneca plc) or Advair (fluticasone/salmeterol, GlaxoSmithKline plc...The market for COPD is estimated at more than $8 billion and growing, and companies like GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co

and GlaxoSmithKline plc will pay generous dividends over the next decade

Few of the pundits and tea-leaf readers handicapping the chances for approval of once-daily inhaled Breo (fluticasone furoate /vilanterol) in the wake of last month's FDA advisory panel were surprised by the agency's go-ahead for the chronic obstructive pulmonary disease (COPD) treatment from GlaxoSmithKline plc and Theravance Inc

GlaxoSmithKline plc (London) UMEC/VI A combination of GSK573719, or umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2 agonist, administered using the ELLIPTA inhaler Chronic obstructive pulmonary disease Submitted a regulatory application in Japan 4/23/13 MISCELLANEOUS Advanced Cell Technology Inc. (Marlborough, Mass.) hESC-RPE Human embryonic stem cell-derived retinal pigment epithelial cells Stargardt's macular dystrophy The first subject in the

GlaxoSmithKline plc (London) Breo Fluticasone furoate (FF)/vilanterol (VI), the combination corticosteroid and long-acting beta2 agonist Chronic obstructive pulmonary disease FDA committee recommended approval 4/18/13 Tris Pharma Inc. (Monmouth Junction, N.J.) Karbinal ER Carbinoxamine maleate extended-release oral suspension Seasonal and perennial allergic rhinitis FDA approved it 4/4/13 MISCELLANEOUS Enlivex Therapeutics Ltd. (Jerusalem) ApoCell A treatment based on inducing immune tolerance

and $7.5 million from partner GlaxoSmithKline plc (GSK) for initiation of a Phase II/III study of ISIS-TTRRX in TTR amyloidosis

GlaxoSmithKline plc's initiative on data transparency took a decisive step forward Tuesday as the company switched on the website that will act as the point of access to its vast repositories of clinical data and named the independent review panel who will control that access

was terminated following HGS' acquisition by GlaxoSmithKline plc

Liquidia's business, meanwhile, remains focused on the vaccine and pulmonary product development platform, including work initiated under its 2012 collaboration with London-based GlaxoSmithKline plc

Despite the recent prominence of TLR biology – Bruce Beutler and Jules Hoffman shared one-half of the 2011 Nobel Prize for their seminal discoveries in the area – it has so far proved to be a less fertile ground for drug companies, with the sole exception being London-based GlaxoSmithKline plc's vaccine adjuvant monophosphoryl lipid A (MPL), a TLR-4 agonist

OBT has ongoing drug development deals with London-based GlaxoSmithKline plc and with Paris-based Sanofi SA

OBT has ongoing drug development deals with London-based GlaxoSmithKline plc and with Paris-based Sanofi SA

Even though the market is crowded with competitors like Nexavar, Sutent (sunitinib, Pfizer Inc.), Torisel (temsirolimus, Pfizer Inc.) and Votrient (pazopanib, GlaxoSmithKline plc), AVEO hoped to clean up by positioning tivozanib as a best-in-class option. (See BioWorld Today, Feb. 17, 2011.) Looking beyond tivozanib's July 28 PDUFA date for the advanced RCC indication, AVEO is developing the drug for other cancers

Impax Pharmaceuticals, of Hayward, Calif., a division of Impax Laboratories Inc., said their collaboration with GlaxoSmithKline plc (GSK) for the development and commercialization of Rytary (IPX066) outside the U.S

The company revealed its intention to split selected respiratory assets that are partnered with London-based GlaxoSmithKline plc (GSK) from its biopharmaceutical operations

Despite the recent prominence of TLR biology – Bruce Beutler and Jules Hoffman shared one-half of the 2011 Nobel Prize for their seminal discoveries in the area – it has so far proved to be a less fertile ground for drug companies, with the sole exception being London-based GlaxoSmithKline plc's vaccine adjuvant monophosphoryl lipid A (MPL), a TLR-4 agonist

In addition to the deals with Celgene and Eisai, Epizyme has racked up a number of collaborations centered on its epigenetics approach, including a 2011 deal with GlaxoSmithKline plc, of London, to discover, develop and commercialize small-molecule inhibitors of HMT, and a recently inked deal with Abbott Park, Ill.-based Abbott to develop a molecular companion diagnostic test for use with EPZ-5676 in MLL